Donald Durden

Title(s)Emeritus Professor, Pediatrics
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer
    NIH R01CA215651Dec 27, 2017 - Jul 31, 2024
    Role: Principal Investigator
    Role of PTEN and PI-3 Kinase in Medulloblastomagenesis
    NIH R01CA172513Jul 3, 2017 - May 31, 2023
    Role: Principal Investigator
    A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma IDE: 74,551
    NIH R01FD005113Sep 30, 2016 - Aug 31, 2020
    Role: Principal Investigator
    Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
    NIH R41CA206859Sep 22, 2016 - Dec 19, 2017
    Role: Principal Investigator
    Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
    NIH R41CA192656Apr 8, 2015 - Jun 30, 2016
    Role: Principal Investigator
    Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
    NIH R01FD004385Sep 5, 2014 - Jul 31, 2018
    Role: Principal Investigator
    Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.
    NIH R21HL091385Jul 1, 2009 - Jun 30, 2011
    Role: Principal Investigator
    Role of Rac2 in Development and Function of Blood Cells
    NIH P01HL069974Apr 22, 2002 - Mar 31, 2008
    Role: Co-Investigator
    Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy
    NIH R01CA094233Dec 1, 2001 - Mar 31, 2013
    Role: Principal Investigator
    Vascular targeted pan PI-3kinase inhibitor prodrug, SF1126 for glioma therapy.
    NIH R56CA094233Dec 1, 2001 - Jun 30, 2009
    Role: Principal Investigator
    Biology and Therapy of High Risk Neuroblastoma
    NIH/NCI P01CA081403Jul 6, 2000 - May 31, 2015
    Role: Co-Investigator
    PHASE II STUDY FOR TREATMENT OF PEDIATRIC BRAIN TUMORS
    NIH R01CA075637Sep 15, 1997 - Jul 31, 2000
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Recent advances in multitarget-directed ligands via in silico drug discovery. Drug Discov Today. 2024 Mar; 29(3):103904. Maddeboina K, Yada B, Kumari S, McHale C, Pal D, Durden DL. PMID: 38280625.
      View in: PubMed   Mentions:    Fields:    
    2. Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies. Leuk Lymphoma. 2023 Dec; 64(14):2333-2337. Smith AL, Pal D, Martinez-Rico R, Eiken AP, Durden DL, Kutateladze TG, El-Gamal D. PMID: 37706519.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies. Biomed Chromatogr. 2023 Aug; 37(8):e5643. Bala V, Chhonker YS, Morales GA, Maddeboina K, Pal D, Durden DL, Murry DJ. PMID: 37042063.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    4. Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection. Structure. 2022 09 01; 30(9):1224-1232.e5. Vann KR, Acharya A, Jang SM, Lachance C, Zandian M, Holt TA, Smith AL, Pandey K, Durden DL, El-Gamal D, Côté J, Byrareddy SN, Kutateladze TG. PMID: 35716662; PMCID: PMC9212912.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    5. PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin Transl Med. 2022 04; 12(4):e806. Acharya A, Pathania AS, Pandey K, Thurman M, Vann KR, Kutateladze TG, Challagundala KB, Durden DL, Byrareddy SN. PMID: 35390226; PMCID: PMC8989379.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia. Front Oncol. 2021; 11:766888. Ruan Y, Kim HN, Ogana HA, Wan Z, Hurwitz S, Nichols C, Abdel-Azim N, Coba A, Seo S, Loh YE, Gang EJ, Abdel-Azim H, Hsieh CL, Lieber MR, Parekh C, Pal D, Bhojwani D, Durden DL, Kim YM. PMID: 34926269; PMCID: PMC8671162.
      View in: PubMed   Mentions: 1  
    7. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. iScience. 2021 Sep 24; 24(9):102931. Pal D, Vann KR, Joshi S, Sahar NE, Morales GA, El-Gamal D, Kutateladze TG, Durden DL. PMID: 34557659; PMCID: PMC8445847.
      View in: PubMed   Mentions: 3  
    8. Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. J Pediatr Hematol Oncol. 2021 04 01; 43(3):e304-e311. Goldin AN, Singh A, Joshi S, Jamieson C, Durden DL. PMID: 33480647.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    9. Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor. bioRxiv. 2021 Mar 05. Acharya A, Pandey K, Thurman M, Challagundala KB, Vann KR, Kutateladze TG, Morales GA, Durden DL, Byrareddy SN. PMID: 33688653; PMCID: PMC7941624.
      View in: PubMed   Mentions: 2  
    10. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics. 2021; 11(2):731-753. Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. PMID: 33391502; PMCID: PMC7738845.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsPHPublic Health
    11. Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma. Cancers (Basel). 2020 Sep 10; 12(9). Gunda V, Pathania AS, Chava S, Prathipati P, Chaturvedi NK, Coulter DW, Pandey MK, Durden DL, Challagundla KB. PMID: 32927667; PMCID: PMC7563727.
      View in: PubMed   Mentions: 11  
    12. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020; 6(1):49. Burgoyne AM, Vann KR, Joshi S, Morales GA, Vega FM, Singh A, Pal D, Merati AB, Kutateladze TG, Durden DL. PMID: 32793389; PMCID: PMC7385619.
      View in: PubMed   Mentions: 6  
    13. Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. Sci Rep. 2020 07 21; 10(1):12027. Vann KR, Pal D, Morales GA, Burgoyne AM, Durden DL, Kutateladze TG. PMID: 32694708; PMCID: PMC7374098.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    14. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 03; 19(3):755-764. Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. PMID: 31974273; PMCID: PMC7450492.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    15. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. PLoS One. 2019; 14(9):e0214901. Chahal KK, Li J, Kufareva I, Parle M, Durden DL, Wechsler-Reya RJ, Chen CC, Abagyan R. PMID: 31539380; PMCID: PMC6754133.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    16. Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. Am J Clin Exp Urol. 2019; 7(4):297-312. Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. PMID: 31511835; PMCID: PMC6734039.
      View in: PubMed   Mentions: 16  
    17. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Mol Cancer Ther. 2019 06; 18(6):1036-1044. Joshi S, Singh AR, Liu KX, Pham TV, Zulcic M, Skola D, Chun HB, Glass CK, Morales GA, Garlich JR, Durden DL. PMID: 31018997; PMCID: PMC6893301.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    18. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. J Oncol. 2019; 2019:5245034. Joshi S, Durden DL. PMID: 30853982; PMCID: PMC6377965.
      View in: PubMed   Mentions: 42  
    19. Erratum to: Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2019 09; 119(9):1546. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden DL, Mosnier LO, von Drygalski A. PMID: 30071568.
      View in: PubMed   Mentions:    Fields:    
    20. Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2018 06; 118(6):1036-1047. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden DL, Mosnier LO, von Drygalski A. PMID: 29847841; PMCID: PMC6191040.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    21. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem. 2018 04 20; 293(16):5808-5820. Campbell GR, Bruckman RS, Herns SD, Joshi S, Durden DL, Spector SA. PMID: 29475942; PMCID: PMC5912471.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    22. Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. PLoS One. 2017; 12(8):e0182851. Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden DL. PMID: 28817691; PMCID: PMC5560537.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    23. The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity. Sci Rep. 2017 01 31; 7:41643. Nguyen HA, Durden DL, Lavie A. PMID: 28139703; PMCID: PMC5282591.
      View in: PubMed   Mentions: 9     Fields:    Translation:Cells
    24. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 02 14; 114(7):E1072-E1080. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG. PMID: 28137841; PMCID: PMC5320964.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    25. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL. PMID: 28881723; PMCID: PMC5581022.
      View in: PubMed   Mentions: 16     Fields:    
    26. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 11; 15(11):2553-2562. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. PMID: 27496136; PMCID: PMC5278767.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    27. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One. 2016; 11(3):e0150836. Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL. PMID: 26938241; PMCID: PMC4777592.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    28. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. PLoS One. 2015; 10(10):e0140585. Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY. PMID: 26473951; PMCID: PMC4608728.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    29. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015 Nov; 90(11):1027-35. Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A. PMID: 26257191; PMCID: PMC4618067.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    30. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015 Mar; 75(3):595-608. Joshi S, Singh AR, Durden DL. PMID: 25578041.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    31. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1):105. Singh AR, Joshi S, George E, Durden DL. PMID: 25425962; PMCID: PMC4243316.
      View in: PubMed   Mentions: 12  
    32. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct; 12(10):1520-31. Joshi S, Singh AR, Zulcic M, Durden DL. PMID: 25103499.
      View in: PubMed   Mentions: 70     Fields:    Translation:AnimalsCells
    33. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. PMID: 24309609; PMCID: PMC4356196.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    34. MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem. 2014 Aug 15; 289(33):22785-22797. Joshi S, Singh AR, Durden DL. PMID: 24982421; PMCID: PMC4132784.
      View in: PubMed   Mentions: 54     Fields:    Translation:AnimalsCells
    35. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10; 327(1):78-90. Singh AR, Peirce SK, Joshi S, Durden DL. PMID: 24881819.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    36. A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis. BMC Immunol. 2014 May 07; 15:18. Joshi S, Singh AR, Zulcic M, Durden DL. PMID: 24886428; PMCID: PMC4017086.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    37. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014; 9(4):e95893. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL. PMID: 24770346; PMCID: PMC4000195.
      View in: PubMed   Mentions: 65     Fields:    Translation:AnimalsCells
    38. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. J Neurooncol. 2014 Jan; 116(1):89-97. Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PMID: 24162827; PMCID: PMC3896301.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    39. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors. J Med Chem. 2013 Mar 14; 56(5):1922-39. Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL. PMID: 23410005.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    40. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol. 2013 Apr; 71(4):867-81. De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL. PMID: 23355037; PMCID: PMC3832139.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    41. Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma. Oncogene. 2013 Aug 29; 32(35):4181-8. Emmenegger BA, Hwang EI, Moore C, Markant SL, Brun SN, Dutton JW, Read TA, Fogarty MP, Singh AR, Durden DL, Yang C, McKeehan WL, Wechsler-Reya RJ. PMID: 23045271; PMCID: PMC3808889.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    42. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer. 2012 Dec; 48(18):3319-27. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK. PMID: 22921184; PMCID: PMC3826796.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    43. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol. 2011 Aug; 68(2):325-35. Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL. PMID: 20972874; PMCID: PMC3143317.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    44. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One. 2010 May 26; 5(5):e10849. Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL. PMID: 20520772; PMCID: PMC2877103.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    45. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer. 2009 Nov 25; 9:411. Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW. PMID: 19939254; PMCID: PMC2790467.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    46. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol. 2010 Mar; 65(4):697-706. Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R. PMID: 19636556; PMCID: PMC2808522.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    47. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell. 2009 May 05; 15(5):363-75. Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M. PMID: 19411066; PMCID: PMC2696306.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCells
    48. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009 Mar 15; 69(6):2540-9. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ. PMID: 19276385; PMCID: PMC2759716.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    49. Expression of RAC2 in endothelial cells is required for the postnatal neovascular response. Exp Cell Res. 2009 Jan 15; 315(2):248-63. De P, Peng Q, Traktuev DO, Traktuevc DO, Li W, Yoder MC, March KL, Durden DL. PMID: 19123268; PMCID: PMC2767303.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    50. PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. Curr Pharm Des. 2009; 15(4):380-8. Castellino RC, Muh CR, Durden DL. PMID: 19199965.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    51. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008 Mar 15; 68(6):1862-71. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL. PMID: 18339867.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    52. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. PMID: 18172313.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansAnimalsCells
    53. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol. 2007 Dec 15; 179(12):8322-31. Li Y, Yan J, De P, Chang HC, Yamauchi A, Christopherson KW, Paranavitana NC, Peng X, Kim C, Munugalavadla V, Munugulavadla V, Kapur R, Chen H, Shou W, Stone JC, Kaplan MH, Dinauer MC, Durden DL, Quilliam LA. PMID: 18056377; PMCID: PMC2722108.
      View in: PubMed   Mentions: 74     Fields:    Translation:AnimalsCells
    54. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007 Dec; 3(12):682-93. Castellino RC, Durden DL. PMID: 18046441.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    55. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol. 2007 Jun; 27(11):4179-97. Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. PMID: 17325034; PMCID: PMC1900023.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    56. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene. 2007 Jun 07; 26(27):3930-40. Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. PMID: 17213812.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    57. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006 Oct 20; 281(42):31222-33. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG. PMID: 16931516.
      View in: PubMed   Mentions: 50     Fields:    Translation:AnimalsCells
    58. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006 Jul 15; 66(14):7067-74. Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ. PMID: 16849552; PMCID: PMC2610484.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    59. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006 Jun; 65(6):529-39. Rong Y, Durden DL, Van Meir EG, Brat DJ. PMID: 16783163.
      View in: PubMed   Mentions: 235     Fields:    Translation:HumansAnimals
    60. CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Exp Cell Res. 2005 Jul 01; 307(1):1-14. Dey N, Howell BW, De PK, Durden DL. PMID: 15890337.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    61. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005 Feb 15; 65(4):1406-13. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PMID: 15735028.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCells
    62. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005 Jan 14; 280(2):1543-51. Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, Geahlen RL. PMID: 15536084.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    63. Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem. 2003 Oct 24; 278(43):41661-9. Pradip D, Peng X, Durden DL. PMID: 12917394.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    64. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003 Jul 01; 63(13):3585-92. Su JD, Mayo LD, Donner DB, Durden DL. PMID: 12839945.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    65. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002 Dec 20; 277(51):49531-7. Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. PMID: 12388538.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    66. SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood. 2002 Sep 01; 100(5):1852-9. Kant AM, De P, Peng X, Yi T, Rawlings DJ, Kim JS, Durden DL. PMID: 12176909.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    67. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood. 2002 Jan 15; 99(2):694-7. Kim JS, Peng X, De PK, Geahlen RL, Durden DL. PMID: 11781256.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    68. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002 Feb 15; 277(7):5484-9. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PMID: 11729185.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCells
    69. Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clin Exp Rheumatol. 2001 Nov-Dec; 19(6):639-46. Reiff A, Zastrow M, Sun BC, Takei S, Mitsuhada H, Bernstein B, Durden DL. PMID: 11791634.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    70. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 2001 Jul 15; 61(14):5587-94. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA. PMID: 11454712.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCells
    71. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A. 2001 Apr 10; 98(8):4622-7. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. PMID: 11274365; PMCID: PMC31884.
      View in: PubMed   Mentions: 84     Fields:    
    72. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000 Feb 01; 60(3):712-21. Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL. PMID: 10676658.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    73. High affinity IgG receptor activation of Src family kinases is required for modulation of the Shc-Grb2-Sos complex and the downstream activation of the nicotinamide adenine dinucleotide phosphate (reduced) oxidase. J Immunol. 1999 Dec 01; 163(11):6023-34. Park RK, Erdreich-Epstein A, Liu M, Izadi KD, Durden DL. PMID: 10570290.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    74. Role of Src in the modulation of multiple adaptor proteins in FcalphaRI oxidant signaling. Blood. 1999 Sep 15; 94(6):2112-20. Park RK, Izadi KD, Deo YM, Durden DL. PMID: 10477741.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    75. Cbl functions downstream of Src kinases in Fc gamma RI signaling in primary human macrophages. J Leukoc Biol. 1999 Apr; 65(4):523-34. Erdreich-Epstein A, Liu M, Kant AM, Izadi KD, Nolta JA, Durden DL. PMID: 10204582.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    76. Characterization of Cbl-Nck and Nck-Pak1 interactions in myeloid FcgammaRII signaling. Exp Cell Res. 1998 Dec 15; 245(2):330-42. Izadi KD, Erdreich-Epstein A, Liu Y, Durden DL. PMID: 9851874.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    77. Differential interaction of Crkl with Cbl or C3G, Hef-1, and gamma subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (Fc gamma RI). J Immunol. 1998 Nov 15; 161(10):5555-63. Kyono WT, de Jong R, Park RK, Liu Y, Heisterkamp N, Groffen J, Durden DL. PMID: 9820532.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    78. SLP-76-Cbl-Grb2-Shc interactions in FcgammaRI signaling. Blood. 1998 Sep 01; 92(5):1697-706. Chu J, Liu Y, Koretzky GA, Durden DL. PMID: 9716598.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    79. CBL-GRB2 interaction in myeloid immunoreceptor tyrosine activation motif signaling. J Immunol. 1998 May 15; 160(10):5018-27. Park RK, Kyono WT, Liu Y, Durden DL. PMID: 9590251.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    80. Protein tyrosine phosphatase inhibitors in Fc gamma RI-induced myeloid oxidant signaling. Exp Cell Res. 1997 Dec 15; 237(2):288-95. Erdreich-Epstein A, Liu M, Liu Y, Durden DL. PMID: 9434624.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    81. Differential activation of the tyrosine kinases ZAP-70 and Syk after Fc gamma RI stimulation. Blood. 1997 Jan 15; 89(2):388-96. Taylor N, Jahn T, Smith S, Lamkin T, Uribe L, Liu Y, Durden DL, Weinberg K. PMID: 9002939.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    82. A role for Shc, Grb2, and Raf-1 in FcgammaRI signal relay. J Biol Chem. 1996 Jun 07; 271(23):13342-8. Park RK, Liu Y, Durden DL. PMID: 8662746.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    83. Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD14-dependent manner. Role of protein tyrosine phosphorylation in lipopolysaccharide-induced stimulation of endothelial cells. J Immunol. 1995 Oct 15; 155(8):3994-4003. Arditi M, Zhou J, Torres M, Durden DL, Stins M, Kim KS. PMID: 7561108.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    84. The Fc gamma RI receptor signals through the activation of hck and MAP kinase. J Immunol. 1995 Apr 15; 154(8):4039-47. Durden DL, Kim HM, Calore B, Liu Y. PMID: 7535819.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    85. Protein-tyrosine kinase p72syk in Fc gamma RI receptor signaling. Blood. 1994 Oct 01; 84(7):2102-8. Durden DL, Liu YB. PMID: 7522622.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    86. Serine/threonine phosphorylation of the gamma-subunit after activation of the high-affinity Fc receptor for immunoglobulin G. Biochem J. 1994 Apr 15; 299 ( Pt 2):569-77. Durden DL, Rosen H, Cooper JA. PMID: 8172619; PMCID: PMC1138309.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    87. Protein tyrosine phosphatase inhibitors block myeloid signal transduction through the Fc gamma RI receptor. Exp Cell Res. 1994 Mar; 211(1):150-62. Durden DL, Rosen H, Michel BR, Cooper JA. PMID: 8125152.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    88. Functions of the major tyrosine phosphorylation site of the PDGF receptor beta subunit. Cell Regul. 1991 Jun; 2(6):413-25. Kazlauskas A, Durden DL, Cooper JA. PMID: 1653029; PMCID: PMC361823.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    89. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res. 1983 Apr; 43(4):1602-5. Durden DL, Salazar AM, Distasio JA. PMID: 6339039.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    90. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int J Cancer. 1982 Sep 15; 30(3):343-7. Distasio JA, Salazar AM, Nadji M, Durden DL. PMID: 6752048.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    91. Alteration in spleen lymphoid populations associated with specific amino acid depletion during L-asparaginase treatment. Cancer Res. 1982 Jan; 42(1):252-8. Distasio JA, Durden DL, Paul RD, Nadji M. PMID: 7032693.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    92. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase-free asparaginase from Vibrio succinogenes on specific ell-mediated cytotoxicity. Int J Cancer. 1981 Jan 15; 27(1):59-65. Durden DL, Distasio JA. PMID: 7019106.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    93. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res. 1980 Apr; 40(4):1125-9. Durden DL, Distasio JA. PMID: 6986981.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    94. Mouse mammary tumor virus (MMTV) antigen(s) are present on B lymphocytes of BALB/c mice. Int J Cancer. 1979 Dec 15; 24(6):813-8. Charyulu V, Sigel MM, Durden DL, Lopez DM. PMID: 94593.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Donald's Networks
    Concepts (513)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California